Compare CKX & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | INTS |
|---|---|---|
| Founded | 1930 | 2012 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 19.2M |
| IPO Year | 1996 | 2021 |
| Metric | CKX | INTS |
|---|---|---|
| Price | $10.75 | $6.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $56.25 |
| AVG Volume (30 Days) | 1.5K | ★ 329.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | 15.22 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $1,521,124.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.86 | ★ N/A |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $8.66 | $0.19 |
| 52 Week High | $13.25 | $8.06 |
| Indicator | CKX | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 59.76 |
| Support Level | $10.25 | $0.29 |
| Resistance Level | $11.20 | $8.06 |
| Average True Range (ATR) | 0.56 | 0.49 |
| MACD | -0.03 | -0.33 |
| Stochastic Oscillator | 15.73 | 18.25 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. CKX has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Surface segment. Geographically, it generates all of its revenue from the United States of America.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.